发布时间：2026-06-24 10:11 Saturnus Bio is a next-generation precision cardiology company that utilizes targeted gene modulation to address rare mono-genetic cardiomyopathies with significant unmet need
The collaboration will augment Merck’s efforts to pursue precision medicine-defined indications
Not intended for Canada-, UK- or US-based media



DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading global science and technology company, today announced a strategic research-stage collaboration with Saturnus Bio, a Versant Ventures-founded biotech, aimed at establishing a foundational portfolio in the promising field of rare genetic cardiomyopathies. This partnership aligns with the company’s commitment to address significant unmet medical needs in rare populations through targeted treatments.

“Through our partnership with Saturnus Bio, we aim to fast track the development of innovative therapies for genetic cardiomyopathies through precision car
=*=*=*=*=*=
当前为第1/5页
下一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页